viewDestiny Pharma PLC

Destiny Pharma presents at the Proactive One2One live investment forum


Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum.

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections.

Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is reporting results in Q1 2021 from  a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA.

It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

Quick facts: Destiny Pharma PLC

Price: 105 GBX

Market: AIM
Market Cap: £62.81 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...



Destiny Pharma mark 'exciting time, completing studies and delivering data'

Destiny Pharma PLC's (LON:DEST) Neil Clarke talks to Proactive London's Katie Pilbeam about the XF-73 Phase 2b clinical trial which is now fully recruited.  The plan is to finalise the phase 2 data in the first quarter then move on to phase 3, with discussions already taking place...

on 7/1/21

2 min read